SCHEMBL3933409

SCHEMBL3933409

NC(=O)c1cc(C(=O)O)co1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.40
ALDH1A1 P00352 3/20 0.38
DHODH Q02127 2/20 0.36
L3MBTL1 Q9Y468 3/20 0.36
PARP15 Q460N3 1/20 0.35
PARP10 Q53GL7 1/20 0.35
TSHR P16473 3/20 0.35
TP53 P04637 2/20 0.35
CA12 O43570 3/20 0.34
CA1 P00915 3/20 0.34
CA2 P00918 3/20 0.34
CA9 Q16790 3/20 0.34
CA7 P43166 2/20 0.34
CA14 Q9ULX7 2/20 0.34
POLB P06746 2/20 0.34
MAPT P10636 2/20 0.34
HSD17B10 Q99714 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
CYP3A4 P08684 1/20 0.34
PARP1 P09874 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28898393 0.86 ALDH1A1 (0.40) ALDH1A1L3MBTL1PARP15PARP10TSHR
SCHEMBL69933 0.84 NR4A2 (0.43) NR4A2ALDH1A1L3MBTL1TSHRTP53
SCHEMBL26907933 0.84 NR4A2 (0.43) NR4A2ALDH1A1L3MBTL1TSHRTP53
Hydrochloric Acid SCHEMBL28355104 0.82 NR4A2 (0.42) NR4A2ALDH1A1L3MBTL1TSHRTP53
Ethylene SCHEMBL22371863 0.80 NR4A2 (0.41) NR4A2ALDH1A1L3MBTL1TSHRTP53
SCHEMBL6234778 0.78 NR4A2 (0.43) NR4A2ALDH1A1L3MBTL1TSHRTP53
SCHEMBL17019793 0.78 L3MBTL1 (0.43) NR4A2ALDH1A1L3MBTL1POLBMAPT
SCHEMBL10161056 0.76 KDM4E (0.39) ALDH1A1L3MBTL1PARP10TSHRPOLB
Butane SCHEMBL3016092 0.75 NR4A2 (0.41) NR4A2ALDH1A1L3MBTL1MAPTTPMT
SCHEMBL1185478 0.75 NR4A2 (0.41) NR4A2ALDH1A1L3MBTL1MAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367673-B2 Substituted diketopiperazines as oxytocin antagonists GLAXO GROUP LIMITED (GB) 2013-02-05 US claimed
US-20090186867-A1 Substituted Diketopiperazines As Oxytocin Antagonists GLAXO GROUP LIMITED 2009-07-23 US claimed
US-7514437-B2 Substituted diketopiperazines as oxytocin antagonists SMITHKLINE BEECHAM CORP. (US) 2009-04-07 US claimed
EP-1458393-B1 SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS GLAXO GROUP LTD (GB) 2008-06-25 EP claimed
CN-100374115-C Substituted diketopiperazines as oxytocin antagonists GLAXO GROUP LTD (GB) 2008-03-12 CN claimed
US-20050148572-A1 Substituted diketopiperazines as oxytocin antagonists GLAXO GROUP LIMITED (GB) 2005-07-07 US claimed
WO-2005000311-A1 SUBSTITUTED DIKETOPIPERAZINES FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA GLAXO GROUP LIMITED (GB) 2005-01-06 WO claimed
EP-1458393-A1 SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2004-09-22 EP claimed
WO-2003053443-A1 SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2003-07-03 WO claimed
US-8541579-B2 Substituted diketopiperazines as oxytocin antagonists GLAXO GROUP LIMITED (GB) 2013-09-24 US disclosed
US-20130131338-A1 SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2013-05-23 US disclosed
US-8367673-B2 Substituted diketopiperazines as oxytocin antagonists GLAXO GROUP LIMITED (GB) 2013-02-05 US disclosed
US-20090186867-A1 Substituted Diketopiperazines As Oxytocin Antagonists GLAXO GROUP LIMITED 2009-07-23 US disclosed
US-7514437-B2 Substituted diketopiperazines as oxytocin antagonists SMITHKLINE BEECHAM CORP. (US) 2009-04-07 US disclosed
CN-100374115-C Substituted diketopiperazines as oxytocin antagonists GLAXO GROUP LTD (GB) 2008-03-12 CN disclosed
US-20050148572-A1 Substituted diketopiperazines as oxytocin antagonists GLAXO GROUP LIMITED (GB) 2005-07-07 US disclosed
WO-2005000311-A1 SUBSTITUTED DIKETOPIPERAZINES FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA GLAXO GROUP LIMITED (GB) 2005-01-06 WO disclosed
EP-1458393-A1 SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2004-09-22 EP disclosed
WO-2003053443-A1 SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2003-07-03 WO disclosed
CN-1228695-A Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta [b] benzofurans LILLY CO ELI (US) 1999-09-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131338-A1 SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS OXTR, AVPR2, CRH NR4A2 996/4885ALDH1A1 4244/4885DHODH 2546/4885
US-20050148572-A1 Substituted diketopiperazines as oxytocin antagonists OXTR, AVPR2, AVPR1B NR4A2 663/4885ALDH1A1 3771/4885DHODH 3042/4885
US-20090186867-A1 Substituted Diketopiperazines As Oxytocin Antagonists OXTR, AVPR2, CRH NR4A2 983/4885ALDH1A1 4327/4885DHODH 2664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.